aibioTheriva special meeting fails quorum, new meeting to be called
Tickers TOVX
A special meeting on share issuance for warrants did not convene because too few shares were present, and the company will call another meeting.
Key facts
- Company
- Theriva Biologics, Inc. (AMEX: TOVX)
- News type
- Company Updates
- Primary source
- Theriva Biologics, Inc. 8-K (2026-04-09)
Theriva Biologics, Inc. (NYSE American: TOVX) reported in a Form 8-K dated April 9, 2026 that it could not hold a special meeting of stockholders that day. The company called the meeting to order, but a sufficient number of shares were not present or represented by proxy to constitute a quorum. The company therefore was not able to convene the meeting, and it has decided to call a new one.
The approvals being sought
The meeting was meant to approve a warrant exercise proposal and an adjournment proposal described in the definitive proxy statement the company filed with the SEC on March 16, 2026. Stockholder approval would allow the issuance of up to an aggregate of 16,184,560 shares of common stock upon exercise of certain common stock purchase warrants, which the filing calls New Warrants.
Those New Warrants were issued under an inducement agreement dated October 16, 2025, between the company and certain institutional investors. The company agreed in that agreement to use its reasonable best efforts to call a stockholder meeting within 60 days after the closing of the transactions contemplated by it, to seek approval of the share issuance.
The obligation to keep calling meetings
The company says it will file proxy materials with the SEC and mail them to stockholders. Those materials will include the date and time of the new meeting, as required. The filing does not give a date for the new meeting. The filing states that, because the meeting did not convene, the company will be required under the inducement agreement to call an additional stockholder meeting every 60 days after that. The obligation runs until stockholder approval is obtained or the New Warrants are no longer outstanding, unless the investors waive it.
The filing is signed by Steven A. Shallcross, who is listed as both Chief Executive Officer and Chief Financial Officer.
The company and its programs
Theriva describes itself as a diversified clinical-stage company developing therapeutics for cancer and related diseases in areas of high unmet need. The company is a Nevada corporation headquartered at 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850, and its common stock trades on the NYSE American under the symbol TOVX. It acquired Theriva Biologics, S.L., formerly VCN Biosciences, S.L., in March 2022 and shifted its focus to oncology. Its lead product candidate, VCN-01, is a clinical-stage oncolytic human adenovirus that is modified for tumor-selective replication. The annual report describes Phase 2b testing of VCN-01 in pancreatic cancer, which the company calls VIRAGE, and a Phase 1 study in retinoblastoma.
The company's earlier focus on gastrointestinal diseases continues in a narrower form. SYN-004 (ribaxamase) is designed to degrade certain intravenous beta-lactam antibiotics in the gut and to reduce acute graft-versus-host disease in transplant recipients. In February 2026, the company granted Rasayana Therapeutics, Inc. an exclusive worldwide license to SYN-020, and Rasayana assumes responsibility and costs for its development and commercialization.
Financial position
The annual report shows research and development expense of $8.6 million for 2025, compared with $12.0 million for 2024. Cash from operations was negative $16.7 million in 2025 and negative $16.9 million in 2024. Year-end cash and cash equivalents were $11.6 million at the end of 2024.
The risks ahead
The company still needs stockholder approval for the warrant share issuance, and the filing gives no date for the new meeting. Until approval comes or the New Warrants are no longer outstanding, it must call a meeting every 60 days unless the investors waive that. If approved, the warrants could bring up to 16,184,560 new shares, which would dilute current holders. Cash from operations was negative $16.7 million in 2025, against year-end 2024 cash and cash equivalents of $11.6 million, and the filings say a SYN-004 trial is pending funding.